Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced results of a European survey that found a child"s Attention Deficit Hyperactivity Disorder (ADHD) symptoms at school were a key concern for parents, yet outside of school their child"s ADHD also had significant impact on parents" personal time.1 The survey also revealed key findings surrounding parents" role in assessment and treatment for their child.1 Additionally, the survey suggested that informational needs may not be met adequately for these children with ADHD and their families.1 Conducted in partnership with ADHD advocacy groups in four EU countries, the survey analysed parental impressions surrounding the impact of ADHD on their child, themselves and their family, as well as their child"s ADHD treatment plan.